Literature DB >> 24627286

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.

Muhammad Furqan1, Yamei Chen, Akintunde Akinleye, Judy Sarungbam, Alan Gass, Karen Seiter, Delong Liu.   

Abstract

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term "mantle cell lymphoma" in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24627286     DOI: 10.1007/s11684-014-0319-1

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  34 in total

1.  Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Authors:  P M Banks; J Chan; M L Cleary; G Delsol; C De Wolf-Peeters; K Gatter; T M Grogan; N L Harris; P G Isaacson; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

Review 2.  Extranodal lymphoma.

Authors:  Judith A Ferry
Journal:  Arch Pathol Lab Med       Date:  2008-04       Impact factor: 5.534

3.  Outcome of deferred initial therapy in mantle-cell lymphoma.

Authors:  Peter Martin; Amy Chadburn; Paul Christos; Karen Weil; Richard R Furman; Jia Ruan; Rebecca Elstrom; Ruben Niesvizky; Scott Ely; Maurizio Diliberto; Ari Melnick; Daniel M Knowles; Selina Chen-Kiang; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

4.  Using primary site as a predictor of survival in mantle cell lymphoma.

Authors:  Alexander J Ambinder; Pareen J Shenoy; Loretta J Nastoupil; Christopher R Flowers
Journal:  Cancer       Date:  2013-01-22       Impact factor: 6.860

5.  Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.

Authors:  N Parry-Jones; E Matutes; R Morilla; V Brito-Babapulle; A Wotherspoon; G J Swansbury; D Catovsky
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

Review 6.  Mantle-cell lymphoma.

Authors:  E Campo; M Raffeld; E S Jaffe
Journal:  Semin Hematol       Date:  1999-04       Impact factor: 3.851

7.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 9.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

Review 10.  MEK and the inhibitors: from bench to bedside.

Authors:  Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.